crypto currencies platform

True Vision: The controlling shareholder and others intend to reduce their holdings by 4% in total;In addition, it is planned to distribute a cash dividend of 12.3 yuan to all shareholders for every 10 shares, with a total dividend of 4.5 billion yuan. In April this year, Ningde has paid dividends of 22 billion yuan, and this time it totaled 27.4 billion yuan. According to the current market value of 11,900, the corresponding dividend yield is 2.3%! It's really not low.Shanghai's action plan for mergers and acquisitions is still very strong! Three years to cultivate 10 head companies, forming a scale of 300 billion mergers and acquisitions, which clearly accelerate the merger of securities companies and build a first-class investment bank. This is a semiconductor leader, a pharmaceutical leader, a new material leader, a brokerage leader, etc., which directly benefits Shanghai local stocks and pays attention to Shanghai's advantages. This time, the merger with assets exceeding 2 trillion is clearly activated, which shows great determination.

China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.Xinhua News Agency: China's monetary policy has changed from "prudent" to "moderately loose" to send a positive signal.Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;

Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.